This study highlights the significance of serum TNFR2 as a useful predictive biomarker for eGFR decline in MGN patients, and it can be used to decide on alternate treatment strategies as well as to monitor and predict the progression to ESRD. The gene discussed is TNFRSF1B; the disease is idiopathic membranous glomerulonephritis.